Unraveling the potential biomarkers of immune checkpoint inhibitors in advanced ovarian cancer: a comprehensive review

被引：1
|
作者：
Na, Jian-rong [1 ]
Liu, Yaqin [2 ]
Fang, Kun [3 ]
Tan, Yuan [2 ]
Liang, Pan-pan [4 ]
Yan, Mei [5 ]
Chu, Jiao-jiao [5 ]
Gao, Jian-mei [5 ]
Chen, Dongsheng [2 ,6 ,7 ]
Zhang, Shu-xiang [1 ]
机构：
[1] Ningxia Med Univ, Clin Coll 1, Dept Resp & Crit Care Med, Yinchuan 750004, Peoples R China
[2] Nanjing Simcere Med Lab Sci Co Ltd, Jiangsu Simcere Diagnost Co Ltd, State Key Lab Neurol & Oncol Drug Dev, Nanjing 210002, Peoples R China
[3] Yinchuan Maternal & Child Hlth Hosp, Yinchuan 750004, Peoples R China
[4] Peoples Hosp Ningxia Hui Autonomous Reg, Yinchuan 750004, Peoples R China
[5] Ningxia Med Univ, Gen Hosp, Yinchuan 750004, Peoples R China
[6] Jinzhou Med Univ, Affiliated Hosp 1, Canc Ctr, Jinzhou, Peoples R China
[7] Jinzhou Med Univ, Affiliated Hosp 1, Ctr Translat Med, Jinzhou, Peoples R China
来源：
INVESTIGATIONAL NEW DRUGS | 2024年 / 42卷 / 06期
关键词：
Ovarian cancer; Immunotherapy; Biomarkers; Genomics; Transcriptomics; Proteomics; PREDICTIVE BIOMARKERS; PLATINUM-RESISTANT; IMMUNOTHERAPY; PEMBROLIZUMAB; COMBINATION;
D O I：
10.1007/s10637-024-01478-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The ongoing research on the role of immunotherapy in advanced ovarian cancer (OC) and current clinical trials indicate that patients shown limited response to immune checkpoint inhibitor (ICI) monotherapy. When combined with other treatments or drugs, the efficacy of immunotherapy will be significantly improved. Biomarkers can be used to identify patients with better responses, thereby improving the precision and efficacy of immunotherapy. Key biomarkers for advanced OC include homologous repair deficiency, programmed death-ligand (PD-L) 1 expression, chemokines, and tumor infiltrating lymphocytes. These biomarkers could be applied in the future to select the most suitable patient populations. This review comprehensively examines the research and development of biomarkers in OC immunotherapy from three omics perspectives: genomics, transcriptomics, and proteomics, which may provide guidance for the effectiveness of OC immunotherapy strategies.
引用
收藏
页码：728 / 738
页数：11
相关论文
共 50 条
  • [1] A comprehensive review of immune checkpoint inhibitors for cancer treatment
    Hossain, Md. Arafat
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [2] Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
    Dal Collo, Giada
    Kamga, Paul Takam
    CANCERS, 2023, 15 (18)
  • [3] Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer
    Pirker, Robert
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 24 - 28
  • [4] Immune checkpoint inhibitors: recent progress and potential biomarkers
    Darvin, Pramod
    Toor, Salman M.
    Nair, Varun Sasidharan
    Elkord, Eyad
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2018, 50 : 1 - 11
  • [5] Immune checkpoint inhibitors: recent progress and potential biomarkers
    Pramod Darvin
    Salman M. Toor
    Varun Sasidharan Nair
    Eyad Elkord
    Experimental & Molecular Medicine, 2018, 50 : 1 - 11
  • [6] Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC
    Wang, Jie
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S157 - S158
  • [7] Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    Bai, Rilan
    Lv, Zheng
    Xu, Dongsheng
    Cui, Jiuwei
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [8] Potential prognostic predictors of treatment with immune checkpoint inhibitors for advanced endometrial cancer
    Yanazume, Shintaro
    Nagata, Chikako
    Kobayashi, Yusuke
    Fukuda, Mika
    Mizuno, Mika
    Togami, Shinichi
    Kobayashi, Hiroaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (01) : 29 - 35
  • [9] Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
    Rilan Bai
    Zheng Lv
    Dongsheng Xu
    Jiuwei Cui
    Biomarker Research, 8
  • [10] Investigating the Therapeutic Potential of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes: A Comprehensive Review and Analysis
    Bharathi, Vanthana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S391 - S392
12345